In silico analyses identified new molecular targets and biomarkers, including the beta-1 adrenergic receptor and the metabolite 7-deoxidoxorubicinone, that may drive doxorubicin-induced cardiotoxicity.
Answers are grounded in this paper and cite their sources.
May guide preclinical validation of beta-1 adrenergic receptor targets; leaves open clinical translation of these in silico findings.
toxicogenomic analyses were conducted using various tools, including the Comparative Toxicogenomic Database, GeneMANIA, Metascape, MIENTURNET, ChEA3, and AutoDock. Additionally, molecular dynamics simulations were performed for 500 ns using Schrödinger software to assess the stability and dynamics of the representative docked complexes. We observed that doxorubicin biotransformed into five metabolites in the human heart and identified 11 common genes related to doxorubicin, its metabolites, dilated cardiomyopathy, and heart failure. Our findings revealed that doxorubicin and its metabolites primarily exhibited binding affinity to the beta-1 adrenergic receptor and fatty acid synthase. Furthermore, we identified several key transcription factors, especially the Homeobox protein Nkx-2.6, and hsa-miR-183-3p associated with this cardiotoxicity. Finally, we observed that, in addition to doxorubicinol, 7-deoxidoxorubicinone, another metabolite of doxorubicin, may also contribute to this cardiotoxicity. These findings contribute to our understanding of the processes underlying doxorubicin-induced chronic cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Karakuş et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: